

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Evelynne DELFOURNE et al.  
Appl. No.: Group:  
Filed: February 12, 2002 Examiner:  
For: PHENANTHROLINE-7-ONE DERIVATIVES AND THEIR  
THERAPEUTIC APPLICATIONS

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION CONCURRENT WITH THE  
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents  
Washington, DC 20231

February 12, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☒ Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☐ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

- a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **FOREIGN SEARCH REPORT OR ACTION**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

**FEES**

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON



Benoit Castel, Reg. No. 35,041

745 South 23<sup>rd</sup> Street  
Arlington, VA 22202  
Telephone (703) 521-2297

BC/bam

Enclosures: ☒ Form PTO-1449(s)  
☒ Documents  
☒ Foreign Search Report  
☐ Other: \_\_\_\_\_

(Use several sheets if necessary)

**0512-1004**

NEW

**Evelyn DELFOURNE et al.**

**F b r u a r y 12, 2002**

Group Art Unit:

[illegible][illegible]

		XP-002036209, LINDSAY et al., "STRUCTURAL REQUIREMENTS FOR BIOLOGICAL ACTIVITY OF THE MARINE ALKALOID ASCIDIDEMIN", Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 7, pp. 739-742, 1995
		XP-002074302, SCHMITZ et al., "BIOLOGICALLY ACTIVE COMPOUNDS FROM MARINE ORGANISMS", Pure & Appl. Chem., Vol. 62, No. 7, pp. 1393-1396, 1990
		XP-002136779, F. BRACHER, "POLYCYCLIC AROMATIC ALKALOIDS", Vol. 52, No. 1, 1997, pp. 57-60

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\* Abstract provided for the Examiner's convenience